Novartis bid to sell new biosimilar crimped by U.S. court battles

ZURICH (Reuters) - Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court battles.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news